That shift, from patching on assumption to patching on evidence, was one of the event's defining moments. BAS doesn't tell ...
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...
The need for therapeutic use exemptions (TUEs) or the permitted use of Prohibited Substances and Prohibited Methods by athletes to treat significant medical conditions arose when several classes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback